Physicians at the ETMC Cardiovascular Institute are among the
first in the U.S. to treat paroxysmal atrial fibrillation patients
with the new Medtronic Arctic Front Advance ™ Cardiac Cryoballoon
System and FlexCath Advance™ Steerable Sheath.
Building upon the proven safety and efficacy of the original
system, Medtronic's second-generation technology provides an
efficient approach to treating this common, yet serious, heart
rhythm condition that affects approximately three million
Tyler Cardiovascular Consultants, P.A. working with ETMC are the
first to bring this technology to East Texas.
The Arctic Front Advance System is used in minimally invasive
procedures to isolate the pulmonary veins using coolant. Delivered
via a catheter, the cryoballoon technology is associated with
faster procedure times than point-by-point radiofrequency ablation
and better treatment outcomes than drug therapies on the market.
Additionally, the Arctic Front Advance cryoballoon features the new
EvenCool™ Cryo Technology, which optimizes the delivery of coolant
inside the balloon; the larger, more uniform cold surface reduces
the effort needed to isolate the pulmonary veins, and improves
physicians' ability to treat patients with complicated anatomies as
compared to the original cryoballoon.
"This next-generation cryoballoon technology provides the same
high-caliber, clinically validated features of its predecessor,
while offering the benefits of greater treatment efficiency,"
said Dr. Raul Torres with Tyler Cardiovascular Consultants.
"By treating patients with the most advanced, clinically relevant
technology, we are better equipped to successfully manage their
atrial fibrillation, thereby improving their overall
The FlexCath Advance Steerable Sheath has a deflection of 135
degrees, compared to the 90 degree deflection rate of its
first-generation predecessor. This greater degree of deflection may
allow the cryoballoon to be better maneuvered and positioned within
the heart to achieve maximum treatment benefit.
The Arctic Front Advance Cryoballoon System and its predecessor
have been used to treat more than 50,000 patients in 32
Atrial fibrillation is the most common and one of the most
undertreated heart rhythm disorders. It is estimated that half of
all diagnosed atrial fibrillation patients fail drug therapy and if
left untreated, patients have up to a five times higher risk of
stroke and an increased chance of developing heart failure.
Paroxysmal atrial fibrillation occurs when irregular heartbeats in
the upper chambers start and stop suddenly on their own, usually
for minutes or days at a time.